All In MedTech

Device Trial Radar · NCT06122935

Evaluation of the Aurora Xi New Nomogram Software 2.0

Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 6,735 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,735

Actual

Start

Nov 27, 2023

Primary completion

Apr 19, 2024

Study completion May 31, 2024

Sponsor

Lead sponsor
Fenwal, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Nov 8, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A clinical trial to evaluate the safety and effectiveness of the Aurora Xi Plasmapheresis System with a new plasma collection volume nomogram.

Conditions

  • Apheresis Related Hypotension

Interventions

  • Aurora Xi New Nomogram Software 2.0Device

    Plasma collection with a proprietary plasma collection volume nomogram provides a more individualized approach to determining the volume of plasma collected from each donor.

  • Aurora Xi Currently Approved Software 1.3Device

    Plasma collection using the currently marketed Optimized Nomogram (software version 1.3) for the Aurora Xi Plasmapheresis System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Significant Hypotensive Adverse EventsTime frame: From venipuncture through 72 hours post-donation.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • BioLife Plasma Services

    Lakeland, Florida

  • BioLife Plasma Services

    West Des Moines, Iowa

  • BioLife Plasma Services

    American Fork, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.